- Home
- SLMBP vs WGSWW Comparison
SLMBP vs WGSWW Comparison
Compare SLMBP & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLMBP
- WGSWW
- Stock Information
- Founded
- SLMBP N/A
- WGSWW 2017
- Country
- SLMBP United States
- WGSWW United States
- Employees
- SLMBP 1710
- WGSWW 1000
- Industry
- SLMBP Finance: Consumer Services
- WGSWW Retail: Computer Software & Peripheral Equipment
- Sector
- SLMBP Finance
- WGSWW Technology
- Exchange
- SLMBP Nasdaq
- WGSWW Nasdaq
- Market Cap
- SLMBP N/A
- WGSWW N/A
- IPO Year
- SLMBP N/A
- WGSWW N/A
- Fundamental
- Price
- SLMBP $73.16
- WGSWW $0.06
- Analyst Decision
- SLMBP
- WGSWW
- Analyst Count
- SLMBP 0
- WGSWW 0
- Target Price
- SLMBP N/A
- WGSWW N/A
- AVG Volume (30 Days)
- SLMBP N/A
- WGSWW 36.6K
- Earning Date
- SLMBP N/A
- WGSWW 02-18-2025
- Dividend Yield
- SLMBP N/A
- WGSWW N/A
- EPS Growth
- SLMBP N/A
- WGSWW N/A
- EPS
- SLMBP N/A
- WGSWW N/A
- Revenue
- SLMBP N/A
- WGSWW $305,450,000.00
- Revenue This Year
- SLMBP N/A
- WGSWW N/A
- Revenue Next Year
- SLMBP N/A
- WGSWW N/A
- P/E Ratio
- SLMBP N/A
- WGSWW N/A
- Revenue Growth
- SLMBP N/A
- WGSWW 50.79
- 52 Week Low
- SLMBP N/A
- WGSWW $0.17
- 52 Week High
- SLMBP N/A
- WGSWW $0.21
- Technical
- Relative Strength Index (RSI)
- SLMBP 29.42
- WGSWW N/A
- Support Level
- SLMBP $72.25
- WGSWW N/A
- Resistance Level
- SLMBP $75.90
- WGSWW N/A
- Average True Range (ATR)
- SLMBP 1.09
- WGSWW 0.00
- MACD
- SLMBP -0.57
- WGSWW 0.00
- Stochastic Oscillator
- SLMBP 6.01
- WGSWW 0.00
About SLMBP SLM Corporation Floating Rate Non-Cumulative Preferred Stock Series B
SLM Corp is an education solutions company. It business is to originate and service loans to students and their families to finance the cost of their education. The provide Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.